Publikationen in Zusammenarbeit mit Forschern von Universitat de Barcelona (5)

2021

  1. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

2020

  1. Factors associated with the number of drugs in darunavir/cobicistat regimens

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 1, pp. 208-214

2004

  1. Clinical, Virologic, and Immunologic Response to Efavirenz- or Protease Inhibitor-Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients with Advanced HIV Infection (EfaVIP 2 Study)

    Journal of Acquired Immune Deficiency Syndromes, Vol. 35, Núm. 4, pp. 343-350

2002

  1. High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/μl and opportunistic diseases: The Efa VIP study (Efavirenz in very immunosuppressed patients)

    AIDS, Vol. 16, Núm. 11, pp. 1554-1556

2001

  1. The role of prices in drug expenditure analysis. An application of price indexes for two therapeutic groups in the Catalan Health Service (1991-1999)

    HEPAC Health Economics in Prevention and Care, Vol. 2, Núm. 4, pp. 142-149